Opiant Pharmaceuticals Inks Deal With Sanofi to Develop Cannabinoid Overdose Treatment
December 26 2018 - 9:39AM
Dow Jones News
By Kimberly Chin
Opiant Pharmaceuticals Inc. (OPNT) has agreed to a licensing
deal with Paris-based Sanofi SA (SAN.FR) to exclusively develop and
commercialize a potential cannabinoid overdose treatment.
Opiant, the maker of opioid overdose drug Narcan, said Wednesday
it will pay Sanofi an upfront fee of $500,000 for drinabant with
further payments contingent upon the achievement of certain
clinical, regulatory and sales benchmarks.
The specialty pharmaceutical company said it intends to develop
drinabant, a cannabinoid CB-1 receptor antagonist, into an
injectable drug which can be used in an emergency department
setting.
Acute cannabinoid overdose is often linked to patients who
ingest large quantities of tetrahydrocannabinol or synthetic
cannabinoid edibles like K2 and Spice, which can be found in the
form of brownies, cookies and candies.
The Santa Monica, Calif.-based company has estimated that acute
cannabinoid overdose has resulted in more than one million
emergency department visits in the U.S., citing data sampled from a
national database and figures from the U.S. Census Bureau. Opiant
said it expects the number to rise as more states legalize
recreational marijuana.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
December 26, 2018 09:24 ET (14:24 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024